Clinical Trial Update: A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

View source ↗

Summary

A post-marketing surveillance trial of cetuximab (Erbitux) plus platinum-based chemotherapy for metastatic or recurrent head and neck squamous cell carcinoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Neoplasms, Squamous Cell | Status: WITHDRAWN